Alvotech Feed

2025-12-31 22:30:00 Alvotech tryggir 100 milljóna dollara fjármögnun

2025-12-31 22:30:00 Alvotech Secures Term Loan Facility of USD 100 Million

2025-12-29 20:40:55 Changes in company's own shares

2025-12-29 20:40:55 Breyting á fjölda eigin hluta

2025-12-22 21:26:00 Alvotechs Finansiella Kalendar för 2026 634,00 ISK | +2,26% | 7,26 MISK

2025-12-22 21:26:00 Fjárhagsdagatal Alvotech fyrir árið 2026 634,00 ISK | +2,26% | 7,26 MISK

2025-12-22 21:26:00 Alvotech’s Financial Calendar for 2026 634,00 ISK | +2,26% | 7,26 MISK

2025-12-22 08:00:00 Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma 3,49 MISK

2025-12-22 08:00:00 Alvotech og Advanz Pharma hefja sölu í Evrópu á fyrstu hliðstæðunni við Simponi 3,49 MISK

2025-12-22 08:00:00 Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma 3,49 MISK

2025-12-19 09:30:00 Alvotech og Teva ná samningi um að sala AVT06 hliðstæðunnar við Eylea má hefjast í Bandaríkjunum á fjórða ársfjórðungi 2026 618,00 ISK | +1,98% | 10,6 MISK

2025-12-19 09:30:00 Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® 618,00 ISK | +1,98% | 10,6 MISK

2025-12-17 08:30:00 Mikil umframeftirspurn alþjóðlegra fjárfesta í útboði Alvotech á breytanlegra skuldabréfum að fjárhæð 108 milljónir dollara 648,00 ISK | -1,82% | 7 057 MISK

2025-12-17 08:30:00 Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering 648,00 ISK | -1,82% | 7 057 MISK

2025-12-16 17:48:34 Alvotech býður út breytanleg skuldabréf að fjárhæð 100 milljónir bandaríkjadala til að viðhalda fjárfestingu í lyfjaþróun, framleiðslu, markaðssetningu og styrkja lausafjárstöðu, staðfestir afkomuspá 2025 og birtir afkomuspá ársins 2026 648,00 ISK | -1,82% | 7 057 MISK

2025-12-16 17:48:34 Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance 648,00 ISK | -1,82% | 7 057 MISK

2025-11-24 11:30:00 Markaðsleyfi veitt á Evrópska efnahagssvæðinu fyrir AVT03, hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva 670,00 ISK | +2,76% | 89,7 MISK

2025-11-24 11:30:00 Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area 670,00 ISK | +2,76% | 89,7 MISK

2025-11-20 10:00:00 Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) 674,00 ISK | +2,12% | 33,9 MISK

2025-11-20 10:00:00 Alvotech og Advanz Pharma fá markaðsleyfi á Evrópska efnahagssvæðinu fyrir Gobivaz, fyrstu hliðstæðuna við Simponi 674,00 ISK | +2,12% | 33,9 MISK

2025-11-12 22:40:00 Alvotech kynnir uppgjör fyrstu níu mánaða ársins 2025 og helstu áfanga í rekstri félagsins 694,00 ISK | -3,07% | 33,6 MISK

2025-11-12 22:40:00 Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update 694,00 ISK | -3,07% | 33,6 MISK

2025-11-10 10:00:00 UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept) 712,00 ISK | +1,71% | 49,6 MISK

2025-11-10 10:00:00 Alvotech vinnur sigur í mikilvægu dómsmáli um framleiðslu og markaðssetningu AVT06 hliðstæðunnar við Eylea (aflibercept) 712,00 ISK | +1,71% | 49,6 MISK

2025-11-10 10:00:00 UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept) 712,00 ISK | +1,71% | 49,6 MISK

2025-11-06 15:07:23 Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA 660,00 ISK | +3,77% | 47,1 MISK

2025-11-06 15:00:00 Alvotech og Advanz Pharma fá markaðsleyfi í Bretlandi fyrir Gobivaz, hliðstæðu við Simponi (golimumab) 660,00 ISK | +3,77% | 47,1 MISK

2025-11-06 15:00:00 Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA 660,00 ISK | +3,77% | 47,1 MISK

2025-11-04 22:01:00 Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update 636,00 ISK | -0,62% | 23,4 MISK

2025-11-04 22:01:00 Alvotech kynnir afkomu fyrstu níu mánaða ársins og ræðir nýjustu áfanga í rekstri félagsins þann 13. nóvember nk. 636,00 ISK | -0,62% | 23,4 MISK

2025-11-02 23:12:42 Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 680,00 ISK | -28,42% | 147 MISK

2025-11-02 23:10:00 Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT05 í Bandaríkjunum 680,00 ISK | -28,42% | 147 MISK

2025-11-02 23:10:00 Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 680,00 ISK | -28,42% | 147 MISK

2025-10-22 11:00:40 Alvotech Announces Changes in Global Business Development and Commercial Operations Team 1010,00 ISK | -0,98% | 4,87 MISK

2025-10-22 11:00:00 Skipulagsbreytingar á viðskiptasviði Alvotech 1010,00 ISK | -0,98% | 4,87 MISK

2025-10-22 11:00:00 Alvotech Announces Changes in Global Business Development and Commercial Operations Team 1010,00 ISK | -0,98% | 4,87 MISK

2025-10-06 10:40:00 Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir fyrirhugaða hliðstæðu Alvotech við líftæknilyfið Xolair 1020,00 ISK | +0,99% | 1,54 MISK

2025-10-06 10:40:00 European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency 1020,00 ISK | +0,99% | 1,54 MISK

2025-09-22 12:15:00 Evrópska lyfjastofnunin mælir með útgáfu markaðsleyfis fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva 968,00 ISK | +0,41% | 4,29 MISK

2025-09-22 12:15:00 European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva® 968,00 ISK | +0,41% | 4,29 MISK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Alvotech

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden